Asana reports Phase Ib data for ASN002 in atopic dermatitis

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from a Phase Ib trial showing that atopic dermatitis candidate ASN002 was well tolerated. The most common adverse events reported were transient, mild headache and nausea. The double-blind, placebo-controlled, U.S. and Canadian trial enrolled 36 patients with moderate to severe atopic dermatitis to receive placebo or once-daily 20, 40 or 80 mg ASN002 for 28 days.

Additionally, the proportion of patients who achieved a ≥50% improvement in Eczema Area and Severity Index (EASI 50) score at day 28 was 29% in the 20 mg ASN002 arm, 100% in the 40 mg ASN002 arm and 88% in the 80 mg ASN002 arm. The three doses of ASN002 also led to mean reductions in patient-reported itch score on a numeric rating scale (NRS) from baseline to day 28 of 15%, 47% and 71%, respectively. Data were presented at the American Academy of Dermatology meeting in San Diego...